Evidence map›Paper›PMID 38455412›Full record

ArticleAmerican journal of cancer research2024

Mineralocorticoid receptor signaling inhibits bladder cancer progression.

Yujiro Nagata, Takuro Goto, Yuki Teramoto, Takuo Matsukawa, Naohiro Fujimoto, Hiroshi Miyamoto

Open access · bronzeAbstract read
In one paragraph

Article in American journal of cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

Yujiro NagataDepartment of Pathology and Laboratory Medicine, University of Rochester Medical Center Rochester, NY, USA.
Takuro GotoDepartment of Pathology and Laboratory Medicine, University of Rochester Medical Center Rochester, NY, USA.
Yuki TeramotoDepartment of Pathology and Laboratory Medicine, University of Rochester Medical Center Rochester, NY, USA.
Takuo MatsukawaDepartment of Pathology and Laboratory Medicine, University of Rochester Medical Center Rochester, NY, USA.
Naohiro FujimotoDepartment of Urology, University of Occupational and Environmental Health School of Medicine Kitakyushu, Japan.
Hiroshi MiyamotoDepartment of Pathology and Laboratory Medicine, University of Rochester Medical Center Rochester, NY, USA.
University of Rochester Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The biological or clinical significance of mineralocorticoid receptor (MR) in urothelial cancer remains largely unknown. The present study aimed to determine the functional role of MR in bladder cancer progression. In two of the human bladder cancer lines expressing MR, treatment with a natural MR ligand, aldosterone, significantly reduced cell proliferation and migration, which was restored by three MR antagonists clinically used, spironolactone (except colony formation of androgen receptor-positive cells cultured in the presence of androgens), eplerenone, and esaxerenone. Similarly, MR knockdown via shRNA virus infection resulted in significant increases in cell viability/migration, as well as colony formation, compared with control sublines. In addition, MR knockdown augmented the expression of β-catenin, c-fos, and N-cadherin, and lowered that of E-cadherin and p53, indicating the induction of the cadherin switching. Immunohistochemistry in surgical specimens detected MR signals in 58 (92.1%; 36.5% weakly-positive/1+, 44.4% moderately-positive/2+, and 11.1% strongly-positive/3+) of 63 muscle-invasive bladder cancers, which was significantly lower than in adjacent non-neoplastic urothelial tissues (100%; 15.7% 1+, 37.3% 2+, and 47.1% 3+). Moreover, patients with MR-high (3+) tumor had a significantly lower risk of cancer-specific mortality (

Indexed as

Aldosteroneanti-mineralocorticoidbladder cancereplerenoneesaxerenonemineralocorticoid receptorspironolactonetumor progressionurothelial carcinoma

Identifiers

PMID38455412
PMCPMC10915320
OpenAlexW4394767699

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.